Frankfurt, Germany - Soluble CD40 ligand can be used to identify ACS patients at highest risk for cardiac events and those who will receive most benefit from the GP IIb/IIIa blocker abciximab, a new ...

WASHINGTON — The investigational anti-CD40 ligand agent dapirolizumab pegol (DZP) outperformed placebo in improving disease activity and reducing high-dose corticosteroid use in patients with systemic ...

Treatment with the investigational CD40 ligand inhibitor frexalimab significantly reduced new MRI lesions in relapsing multiple sclerosis (MS) by week 24, according to data presented at the joint ...

BOSTON--(BUSINESS WIRE)--Boston Immune Technologies and Therapeutics, Inc. (BITT), a clinical-stage biotechnology company developing novel tumor necrosis factor superfamily receptor (TNFSR) antagonist ...

BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory systemic lupus erythematosus (SLE) get symptoms under control, according ...

Eledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell ...

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies PURPOSE: To determine the toxicity, ...

The CD40–CD40L costimulatory pathway regulates adaptive and innate immune responses and has been implicated in the pathogenesis of multiple sclerosis. Frexalimab is a second-generation anti-CD40L ...

Phase II Study of Peri- and Post-Transplant Ruxolitinib for Patients With Myelofibrosis Receiving Allogeneic Hematopoietic Cell Transplantation BMS-986004, a single, one-time dose of 1,500 mg was ...

Over the past 20 years, a class of anticancer drugs called CD40 agonist antibodies has shown great promise but also induced great disappointment. While such drugs have been effective at activating the ...